Therapeutic advances of tadalafil in multi-organ systemic diseases beyond erectile dysfunction
10.13263/j.cnki.nja.2025.11.010
- VernacularTitle:他达拉非在非勃起功能障碍的多器官系统疾病中的治疗进展
- Author:
Fan YAO
1
;
Junjie WU
;
Xuejun SHANG
Author Information
1. 南京中医药大学金陵临床医学院,南京 210002
- Publication Type:Journal Article
- Keywords:
phosphodiesterase type 5;
tadalafil;
NO-cGMP signaling pathway;
multi-organ systemic diseases
- From:
National Journal of Andrology
2025;31(11):1021-1026
- CountryChina
- Language:Chinese
-
Abstract:
Phosphodiesterase type 5(PDE5)participates in the physiological functions of multiple organs by regulating the nitric oxide(NO)-cyclic guanosine monophosphate(cGMP)pathway.As a long-acting PDE5 inhibitor,tadalafil has been used clinically for over 20 years and is approved for the treatment of male erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia.Furthermore,tadalafil maintains cGMP levels by inhibiting PDE5,thereby activa-ting the downstream NO-cGMP signaling pathway to exert multiple effects,including relaxing smooth muscle,exerting antioxidant actions,regulating apoptosis,and modulating metabolism.Clinical evidence indicates that tadalafil shows promising therapeutic potential in multi-organ system diseases such as pulmonary arterial hypertension,heart failure,type 2 diabetes,cognitive impair-ment,female infertility,and fetal growth restriction.This article systematically reviews the action mechanisms and research pro-gress of tadalafil in treating diseases beyond erectile dysfunction,aiming to summarize its potential for cross-disease system clini-cal applications and provide references for optimizing treatment strategies for patients with chronic diseases.
